the classical drugs used to decrease prolactin production and release from the pituitary, do not affect production of prolactin in nonpituitary tissues Prolactin-receptor antagonists are ...

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

Estrogen agonists/antagonists are compounds with tissue-selective ... Currently approved drugs in the USA in this class include tamoxifen citrate (e.g., Nolvadex®), raloxifene hydrochloride ...

Despite the initial effectiveness of drugs that target the estrogen receptor, many patients eventually develop resistance, making therapies ineffective. This new discovery could result in more ...

Raloxifene can be classified as a second-generation SERM. A SERM interacts with estrogen receptors, functioning as an estrogen agonist in some tissues and an antagonist in other tissues.

Estrogens are known to drive tumor growth in breast cancer cells that carry its receptors ... the researchers found that anti ...

A phase 3 clinical trial has shown that adding a targeted immunotherapy drug to chemotherapy dramatically improved – almost ...

Olema's lead product candidate, palazestrant, is currently in a Phase 3 clinical trial, which is a critical stage in the drug development ... complete estrogen receptor antagonist and selective ...